Top Markets
Coin of the day
AegirBio AB (publ) AegirBio AB (publ)

AegirBio AB (publ)

AEGIR
Rank in Stocks #38668
AegirBio AB (publ) is a diagnostics firm established in 2019 in Lund, Sweden.... AegirBio AB (publ) is a diagnostics firm established in 2019 in Lund, Sweden. The company specializes in developing and commercializing tests primarily aimed at monitoring the dosage of biological drugs. Their efforts are concentrated on therapeutic drug monitoring for biologic therapies across various conditions, including multiple sclerosis, different types of cancer, and autoimmune diseases. Among their offerings are moNATor, a pioneering laboratory test designed for dose monitoring in multiple sclerosis for both medical professionals and patients, and Viraspec, a saliva-based test kit for COVID-19 detection.
Share Price
$0.04057595
Last synced: 2024-08-05
Market Cap
$863.62K
Change (1 day)
0.31%
Change (1 year)
0.00%
Country
SE
Trade AegirBio AB (publ) (AEGIR)

Category

P/E ratio for AegirBio AB (publ) (AEGIR)
P/E ratio as of August 2026 TTM: -0.18
According to AegirBio AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.18. At the end of 2022 the company had a P/E ratio of -0.11.
P/E ratio history for AegirBio AB (publ) from 2019 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.18 -63.31%
2023 -0.49 361.47%
2022 -0.11 -98.95%
2021 -10.13 -58.60%
2020 -24.47 -99.99%
2019 -309.20K 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
39.92 -22,304.84%
US
30.38 -16,996.33%
FR
- -
JP
41.93 -23,419.86%
US
- -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.